Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Change in Account Payables (2020 - 2024)

Immuneering has reported Change in Account Payables over the past 5 years, most recently at $56741.0 for Q4 2024.

  • Quarterly results put Change in Account Payables at $56741.0 for Q4 2024, down 66.73% from a year ago — trailing twelve months through Dec 2024 was -$112143.0 (up 89.87% YoY), and the annual figure for FY2025 was -$400799.0, down 257.4%.
  • Change in Account Payables for Q4 2024 was $56741.0 at Immuneering, up from -$679454.0 in the prior quarter.
  • Over the last five years, Change in Account Payables for IMRX hit a ceiling of $1.1 million in Q3 2022 and a floor of -$778202.0 in Q3 2023.
  • Median Change in Account Payables over the past 5 years was $90557.0 (2021), compared with a mean of $55249.7.
  • Biggest five-year swings in Change in Account Payables: crashed 731.07% in 2022 and later skyrocketed 675.42% in 2024.
  • Immuneering's Change in Account Payables stood at $274072.0 in 2020, then tumbled by 262.37% to -$445014.0 in 2021, then skyrocketed by 283.4% to $816177.0 in 2022, then crashed by 79.1% to $170568.0 in 2023, then plummeted by 66.73% to $56741.0 in 2024.
  • The last three reported values for Change in Account Payables were $56741.0 (Q4 2024), -$679454.0 (Q3 2024), and $393177.0 (Q2 2024) per Business Quant data.